Journal: Journal of Pharmaceutical Analysis

Article Title: Hyaluronic acid-modified polymeric nanoplatform delivering 131 I-Hyp suppresses post-ablation residual lesions in colorectal cancer metastases via necrosis-targeted radiotherapy

doi: 10.1016/j.jpha.2025.101488

Figure Lengend Snippet: CD44 receptor expression and HA-PCL@( 131 I-Hyp) nanoparticles (HP-NPs) binding affinity in vitro . (A) Immunocytochemistry of CD44 expression in HT-29 and HCT-15 cells assessed by fluorescence microscopy with a fluorescein isothiocyanate (FITC) dye. (B) Flow cytometry analysis of CD44 surface expression in HT-29 and HCT-15 colorectal cancer cell lines. Cells were analyzed using unstained isotype controls for gating. CD44-positive cells represented 86.8% of the HT-29 population versus 0.65% of the HCT-15 population. (C) Intracellular distribution of fluorescence from hypericin (Hyp) at 0.5, 1, and 2 h posttreatment in HT-29 cells, HCT-15 cells, and HT-29 cells treated with free hyaluronic acid (HA). Red fluorescence: Hyp; blue fluorescence: Hoechst. (D, E) Flow cytometry (D) and quantitative analysis (E) of the fluorescence intensity of HT-29 and HCT-15 cells incubated with the same concentration of HP-NPs. ∗ P < 0.05, ns: no significant. HA-PCL: hyaluronan- b -poly(ε-caprolactone); DAPI: 4',6-diamidino-2-phenylindole.

Article Snippet: Anti-human/mouse CD44 conjugated with fluorescein isothiocyanate (FITC) (F1104401; Lianke Biotech Co., Ltd., Hangzhou, China) was added to the cells in the experimental groups at a 1:20 dilution in flow staining buffer, and the mixture was incubated at room temperature for 15 min in the dark.

Techniques: Expressing, Binding Assay, In Vitro, Immunocytochemistry, Fluorescence, Microscopy, Flow Cytometry, Incubation, Concentration Assay

Journal: Cell Transplantation

Article Title: Bone marrow mesenchymal stem cells attenuate pain and modulate peripheral sodium channel activity in a rat model of complex regional pain syndrome type I

doi: 10.1177/09636897251383588

Figure Lengend Snippet: Morphological observation, surface marker characterization, and multipotent differentiation potential of primary rat BMSCs. (a) Morphology of primary rat BMSCs observed under an inverted microscope. (b) Flow cytometry analysis of the surface marker CD105 in third-generation BMSCs using FITC-conjugated anti-CD105 antibody. (c) Flow cytometry analysis of the surface marker CD90 in third-generation BMSCs using PE-conjugated anti-CD90 antibody. (d) Flow cytometry analysis of the surface marker CD44 in third-generation BMSCs using FITC-conjugated anti-CD44 antibody. (e) Flow cytometry analysis of the surface marker CD45 in third-generation BMSCs using PE-conjugated anti-CD45 antibody. (f) Flow cytometry analysis of the surface marker CD11b in third-generation BMSCs using PE-conjugated anti-CD11b antibody. (g) Oil Red O staining for adipogenic differentiation of BMSCs, showing lipid droplet formation. (h) Alizarin Red staining for osteogenic differentiation of BMSCs, showing calcium nodule formation ( n = 3).

Article Snippet: Antibodies for flow cytometry included FITC-CD44, PE-CD45, PE-CD90, PE-CD11b (eBioscience, CA, USA), and FITC-CD105 (Bio-Rad, CA, USA).

Techniques: Marker, Inverted Microscopy, Flow Cytometry, Staining

Journal: Nature Communications

Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

doi: 10.1038/s41467-025-65056-9

Figure Lengend Snippet: a Flow cytometric analysis of anti-PD-L1-stained cells in tumor tissues after different treatments ( n = 5 independent mice). b Quantification of the percentage of PD-L1 positive cells in ( a ) ( n = 5 independent mice). c Schematic diagram of the mechanism of Sv@PM-M2p-mediated upregulation of PD-L1 within HCC TME. d Schematic illustration of the research procedure in bilateral subcutaneous HCC mouse model. e Representative bioluminescence images of bilateral subcutaneous HCC mice at specific time points with different treatments ( n = 5 independent mice). f Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). g Flow cytometric analysis of anti-F4/80/CD206-stained macrophages and anti-F4/80/CD86-stained macrophages in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of F4/80 + CD206 + M2 TAMs and F4/80 + CD86 + M1 TAMs in ( g ) ( n = 5 independent mice). i Flow cytometric analysis of anti-CD44/CD62L-stained T cells (gated on CD3 + CD8 + T cells) in the spleens after different treatments ( n = 5 independent mice). j Quantification of the percentage of CD44 + CD62L - memory T cells in ( i ) ( n = 5 independent mice). k The assay of IFN-γ, TNF, IL-6, and IL-12 in serum after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , f , h , j , k ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 8c, d were created by Adobe Illustrator.

Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

Techniques: Staining